CVTX gets SPA for another Ranexa trial

CV Therapeutics (CVTX) received an SPA from FDA for a Phase III trial of Ranexa ranolazine to treat chronic angina. CVTX plans to begin the international double-blind, placebo-controlled study in about 500 patients next quarter. The primary endpoint is angina frequency. If successful, the trial will serve as the primary basis for approval. ...